PMID- 18164920
OWN - NLM
STAT- MEDLINE
DCOM- 20080205
LR  - 20221207
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 29 Suppl
DP  - 2007
TI  - Duloxetine for the management of diabetic peripheral neuropathic pain: 
      evidence-based findings from post hoc analysis of three multicenter, randomized, 
      double-blind, placebo-controlled, parallel-group studies.
PG  - 2536-46
LID - 10.1016/j.clinthera.2007.12.002 [doi]
AB  - OBJECTIVE: This post hoc analysis was aimed to summarize the efficacy and 
      tolerability of duloxetine as represented by number needed to treat (NNT) and 
      number needed to harm (NNH) to provide a clinically useful assessment of the 
      position of duloxetine among current agents used to treat diabetic peripheral 
      neuropathic pain (DPNP). METHODS: Data were pooled from three 12-week, 
      multicenter, randomized, double-blind, placebo-controlled, parallel-group studies 
      in which patients received 60 mg duloxetine either QD or BID or placebo. NNT was 
      calculated based on rates of response (defined as >or=30% and >or=50% reductions 
      from baseline in the weekly mean of the 24-hour average pain severity scores); 
      NNH was calculated based on rates of discontinuation due to adverse events (AEs). 
      RESULTS: Patients receiving duloxetine 60 mg QD and 60 mg BID had NNTs (95% CI) 
      of 5.2 (3.8-8.3) and 4.9 (3.6-7.6), respectively, based on last observation 
      carried forward; NNTs of 5.3 (3.8-8.3) for 60 mg QD and 5.7 (4.1-9.7) for 60 mg 
      BID were obtained based on baseline observations carried forward. The NNHs (95% 
      CI) based on discontinuation due to AEs were 17.5 (10.2-58.8) in the duloxetine 
      60-mg QD group and 8.8 (6.3-14.7) in the 60-mg BID group. CONCLUSION: These post 
      hoc results suggest that duloxetine was effective and well tolerated for the 
      management of DPNP and further support the importance of duloxetine as a 
      treatment option for clinicians and patients to assist with the management of 
      DPNP.
FAU - Kajdasz, Daniel K
AU  - Kajdasz DK
AD  - Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, 
      USA. kaidasz_daniel_k@lilly.com
FAU - Iyengar, Smriti
AU  - Iyengar S
FAU - Desaiah, Durisala
AU  - Desaiah D
FAU - Backonja, Misha-Miroslav
AU  - Backonja MM
FAU - Farrar, John T
AU  - Farrar JT
FAU - Fishbain, David A
AU  - Fishbain DA
FAU - Jensen, Troels S
AU  - Jensen TS
FAU - Rowbotham, Michael C
AU  - Rowbotham MC
FAU - Sang, Christine N
AU  - Sang CN
FAU - Ziegler, Dan
AU  - Ziegler D
FAU - McQuay, Henry J
AU  - McQuay HJ
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0 (Thiophenes)
RN  - 9044SC542W (Duloxetine Hydrochloride)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Diabetic Neuropathies/*drug therapy
MH  - Double-Blind Method
MH  - Duloxetine Hydrochloride
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuralgia/*drug therapy
MH  - Peripheral Nervous System Diseases/*drug therapy
MH  - Selective Serotonin Reuptake Inhibitors/*therapeutic use
MH  - Thiophenes/*therapeutic use
EDAT- 2008/01/26 09:00
MHDA- 2008/02/06 09:00
CRDT- 2008/01/26 09:00
PHST- 2007/09/19 00:00 [accepted]
PHST- 2008/01/26 09:00 [pubmed]
PHST- 2008/02/06 09:00 [medline]
PHST- 2008/01/26 09:00 [entrez]
AID - S0149-2918(07)00370-0 [pii]
AID - 10.1016/j.clinthera.2007.12.002 [doi]
PST - ppublish
SO  - Clin Ther. 2007;29 Suppl:2536-46. doi: 10.1016/j.clinthera.2007.12.002.